Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates

Autor: Krystle A. Lang Kuhs, Carolina Porras, John T. Schiller, Ana Cecilia Rodriguez, Mark Schiffman, Paula Gonzalez, Sholom Wacholder, Arpita Ghosh, Yan Li, Douglas R. Lowy, Aimée R. Kreimer, Sylviane Poncelet, John Schussler, Wim Quint, Leen-Jan van Doorn, Mark E. Sherman, Mary Sidawy, Rolando Herrero, Allan Hildesheim, Mahboobeh Safaeian, Steve Self, Adriana Benavides, Luis Diego Calzada, Ruth Karron, Ritu Nayar, Nancy Roach, Joanna Cain, Diane Davey, David DeMets, Francisco Fuster, Ann Gershon, Elizabeth Holly, Henriette Raventós, Wasima Rida, Luis Rosero-Bixby, Kristen Suthers, Silvia Lara, Sarah Thomas, Mario Alfaro, Manuel Barrantes, M. Concepción Bratti, Fernando Cárdenas, Bernal Cortés, Albert Espinoza, Yenory Estrada, Paula González, Diego Guillén, Roland Herrero, Silvia E. Jiménez, Jorge Morales, Luis Villegas, Lidia Ana Morera, Elmer Pérez, Ana Cecilia Rodríguez, Libia Rivas, Enrique Freer, José Bonilla, Alfanso García-Piñeres, Sandra Silva, Ivannia Atmella, Margarita Ramírez, Nora Macklin, Mark Sherman, Diane Solomon, Ligia Pinto, Troy Kemp, Claire Eklund, Martha Hutchinson

Publikováno v: American journal of epidemiology. 180(6)

Two trials of clinically approved human papillomavirus (HPV) vaccines, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE I/II) and the Papilloma Trial Against Cancer in Young Adults (PATRICIA), reported a 22% difference in vacci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff11af4fcbd4bf2c7e44ec4e98fc8c6
https://pubmed.ncbi.nlm.nih.gov/25139208